In line with broadening geography of pharma markets, W-K ‘glocalizes’ its services
A longtime leader in medical communications services, Wolters Kluwer Pharma Solutions (Bridgewater, NJ) has branded a new service, inScience Communications, with two goals in mind: to combine its scientific and medical writing capabilities, and to streamline the process of conveying medical information developed in the US or Europe to emerging pharma markets in Latin America and Asia. The company says that it has extensive “local expertise” in countries around the globe whose efforts can be coordinated with global management. In doing so, it expects to mirror the efforts of most multinational pharma companies, who are looking to tap into the faster growth of emerging markets.
The status of medical communications itself is changing, says Bryce Murray, GM, Global Medical Communications at W-K. Critics have railed against the industry’s outsourcing (“ghostwriting”) of medical communications—including the composition of peer-reviewed articles and reports—but says that a few bad actors have tarnished the entire business service. Organizations like the International Committee of Medical Journal Editors (icmje.org) have already written tighter standards that will be applied by many leading biomedical journals, and the field of medical writing itself is trying to professionalize. (ICMJE’s standards include divulging the participation of outside writers or other whiting services.) “We’re living in a transparency-driven world,” he says.
On the other hand, the need for quality medical writing has never been higher, he says, noting that the growth of pharma and biotech research in Asia has led to the growth of non-English-language journals there. A related part of Wolters Kluwer Pharma Solutions is providing advice on where to publish.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.